The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rational and current status of estrogen priming are reviewed.
|Original language||English (US)|
|Number of pages||4|
|Journal||Drug Intelligence and Clinical Pharmacy|
|State||Published - 1988|
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)